Artivion, Inc. AORT 深滬

已收盤 02-06 16:00:00 美东时间

39.59

+0.130

+0.33%

華盛通

立即下載

最高40.17
今開40.00
成交量 29.10万股
最低 39.35
昨收 39.46
總市值 18.76亿
52周最高 48.25
市盈率 ^靜 --
換手率 0.61%
52周最低 21.97
委比 -50.00%
總股本 4737.49万
歷史最高 48.25
量比 0.69
振幅 2.08%
歷史最低 3.82
每手 1
風險率 8.35%

個股概要

財務分析

公司資料

分紅派息

分時圖
日k
周k
月k

相關新聞

美股大行评级 | 高露洁棕榄、再生元制药、伊士曼化工、威瑞森、Ameris、丘奇＆德怀特等获多家大行上调目标价

今日重点评级关注：Benchmark：维持Charter Communications"买入"评级，目标价从425美元升至455美元；BTIG：维持LifeStance Health Gr"买入"评级，目标价从10美元升至11美元

02-03 09:06
The Analyst Verdict: Artivion In The Eyes Of 4 Experts

4 analysts have expressed a variety of opinions on Artivion (NYSE:AORT) over th...

02-03 06:00
Needham Reiterates Buy on Artivion, Maintains $58 Price Target

Needham analyst Mike Matson reiterates Artivion (NYSE:AORT) with a Buy and maintains $58 price target.

02-03 01:59
Artivion Reports Strong Survival and Low Morbidity in NEXUS TRIOMPHE and AMDS PERSEVERE Trials

Artivion Reports Strong Survival and Low Morbidity in NEXUS TRIOMPHE and AMDS PERSEVERE Trials Artivion Inc. has announced the presentation of new clinical data from two trials—the NEXUS TRIOMPHE IDE trial and the AMDS PERSEVERE IDE trial—at the 62nd Annual Meeting of the Society of Thoracic Surgeon

02-02 21:01
Alphatec is the top performing healthcare equipment stock YTD

The S&P healthcare index (XLV) saw moderate gains in 2025, reaching a YTD increase of 12.2% by mid-December, though it fell short of its May highs. The sector is the sixth-highest performing sector a...

2025-12-23 01:12
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级

今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元

2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级

今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元

2025-11-10 10:22
Artivion Q3 Adj. EPS $0.16, Sales $113.388M Beat $110.437M Estimate

Artivion (NYSE:AORT) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.02 by 841.18 percent. This is a 33.33 percent increase over earnings of $0.12 per share from the same

2025-11-07 05:34
Artivion Treats First Patient In ARTIZEN Pivotal Study Evaluating Arcevo LSA Hybrid Stent Graft System For Acute, Chronic Arch Pathologies

Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the treatment of the first patient in the ARTIZEN pivotal trial, evaluating the safety and

2025-11-06 21:36

公司名稱	Artivion, Inc.
行業分類	Medical Specialties
業務描述	Artivion, Inc. engages in the manufacture, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment offers cardiac and vascular tissue preservation services. The company was founded on January 19, 1984, and is headquartered in Kennesaw, GA.

派息除權日	每股總股息	派息日期
2015-12-09	0.03	2015-12-18
2015-09-09	0.03	2015-09-18
2015-06-10	0.03	2015-06-19
2015-03-11	0.03	2015-03-20
2014-12-10	0.03	2014-12-19
2014-09-10	0.03	2014-09-19
2014-06-11	0.03	2014-06-20
2014-03-12	0.03	2014-03-21
2013-12-11	0.03	2013-12-20
2013-09-11	0.03	2013-09-20
2013-06-12	0.03	2013-06-21
2013-03-12	0.03	2013-03-21
2012-12-12	0.03	2012-12-21
2012-09-12	0.03	2012-09-21

Artivion, Inc. AORT 深 滬

39.59

個股概要

財務分析

公司資料

相關新聞

分紅派息

相關新聞

公司簡介

Artivion, Inc. AORT 深滬